d-609 has been researched along with undecanoic-acid* in 3 studies
3 other study(ies) available for d-609 and undecanoic-acid
Article | Year |
---|---|
Mechanistic aspects of the synergistic antiviral effect of xanthates and monocarbonic acids.
The xanthate tricyclodecan-9-yl-xanthogenate (D609) displays antiviral and antitumoral properties that are inversely proportional in vitro to the serum concentration. Accordingly, it has been found that D609 binds to serum albumin. Recently, we have reported that D609, in combination with undecanoic acid, has a synergistic antiviral effect, which appears, as shown here, to be due to competition for the same binding domain on serum albumin. Furthermore, undecanoic acid fosters the binding of D609 to the cell. Both the competition of D609 with monocarbonic acid for binding on serum albumin and the enhanced binding of xanthate to the cell are dependent, in accordance with previously reported results, on the chain length of the fatty acids. Eleven to 14 C-atoms (undecanoic, lauric and myristic acid) were found to be appropriate while shorter (C6) and larger (C18) monocarbonic acids were shown to lack synergistic properties. Topics: Binding, Competitive; Bridged-Ring Compounds; Chromatography, Liquid; Drug Synergism; Fatty Acids; Norbornanes; Serum Albumin, Bovine; Thiocarbamates; Thiones; Vesicular stomatitis Indiana virus; Virus Replication | 1989 |
Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitro.
Xanthate derivatives were shown previously to display antitumor activity against transformed fibroblasts and lymphoma cells in combination with monocarboxylic acids [1]. Various malignant cell lines of human origin were treated in vitro to explore the range of antitumoral activity of the compounds. The combination of tricyclodecan-9-yl-xanthogenate (D 609) with undecanoic acid (C11) exerted dose dependent cytotoxic and antiproliferative effects on cell lines both from solid tumors (glioblastomas, colon-carcinomas) and hematological diseases (lymphomas, CML/BC). Additionally, the combination of D 609/C11 was able to kill both methotrexate- and adriamycin-resistant L 1210 and S 180 cells, indicating that there is no cross-resistance for these drugs and D 609/C11 in vitro. Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Resistance; Fatty Acids; Humans; Neoplasms; Norbornanes; Thiocarbamates; Thiones; Tumor Cells, Cultured | 1989 |
Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo.
The combinations of tricyclodecan-9-yl-xanthogenate (D 609) with undecanoic acid (C11) and D 609 with myristic acid (C14) were tested in 3 rodent tumor models in vivo. D 609 in combination with C11 or C14 did not show antitumoral efficacy in 3-Lewis lung carcinoma (3-LL) growing in syngeneic C57BL6-mice (primary tumor and metastasis) or in WEHI-3B myelomonocytic leukemia growing in Balb/c mice, when given in a dose range lower than the lethal dose for 10% of the treated animals (LD10). In L 1210 mouse lymphoid leukemia growing in CD2F1 mice the combination of D 609/C11 given intraperitoneally in a concentration of 100 mg/kg for more than 1 day effected a significant difference in the survival curves between the control and therapeutic groups in 1 out of 2 experiments. In conclusion, the treatment schedules of D 609/C11 or D 609/C14 used in this study has not revealed significant therapeutic effects in mouse tumors or leukemias in vivo. Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Fatty Acids; Female; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myristic Acids; Neoplasms, Experimental; Norbornanes; Thiocarbamates; Thiones | 1989 |